PaulRPentelMD
Internal Medicine • Minneapolis, MNProfessor, Medicine, University of Minnesota Medical School, Minneapolis
Are you Dr. Pentel?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 41 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
701 Park Ave
Minneapolis, MN 55415Phone+1 612-873-2300Fax+1 612-904-4299
Summary
- Dr. Paul Pentel, MD is a board certified internist in Minneapolis, Minnesota. He is currently licensed to practice medicine in Minnesota. He is affiliated with Hennepin Healthcare and is a Professor at University of Minnesota Medical School.
Education & Training
Hennepin HealthcareResidency, Internal Medicine, 1975 - 1979
Stanford University School of MedicineClass of 1975
Certifications & Licensure
MN State Medical License 1976 - 2025- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Effects of Dynorphin 1-13 on Heroin Addiction - 1 Start of enrollment: 1994 Aug 01
Publications & Presentations
PubMed
- 8 citationsA TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models.Bethany Crouse, Shannon M Miller, Peter Muelken, Linda Hicks, Jennifer R Vigliaturo
NPJ Vaccines. 2023-07-24 - 5 citationsPre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.Fatima A Hamid, Cheryl L Marker, Michael D Raleigh, Aaron Khaimraj, Scott Winston
Vaccine. 2022-05-20 - 4 citationsAttenuating nicotine's effects with high affinity human anti-nicotine monoclonal antibodies.Michael D. Raleigh, Nicola Beltraminelli, Stéphanie Fallot, Mark G. LeSage, Amy Saykao
Plos One. 2021-07-30
Press Mentions
To Fight Opioid Crisis, UW Researchers Take New Shot at Developing Vaccine Against Addictive DrugsJanuary 5th, 2022
Grant Support
- Preclinical Studies Of A Heroin/Morphine Vaccine For Opiate AddictionNational Institute On Drug Abuse2010–2011
- Multivalent Vaccine For Opiate AddictionNational Institute On Drug Abuse2008–2011
- Immunization To Block The Effects Of NicotineNational Institute On Drug Abuse2000–2011
- Project 2: Nicotine Exposure Reduction In RatsNational Institute On Drug Abuse2004–2008
- TSE Inhalation System: Tobacco &NicotineNational Center For Research Resources2005
- TSE Inhalation System: Tobacco &Bone HealingNational Center For Research Resources2005
- TSE Inhalation System: Lung CancerNational Center For Research Resources2005
- TSE Inhalation System: Adult Human Stem CellNational Center For Research Resources2005
- TSE Inhalation SystemNational Center For Research Resources2005
- Vaccine Effects On Fetal Nicotine Exposure In RatsNational Institute On Drug Abuse2002–2005
- Effects Of Nicotine Vaccine In RatsNational Institute On Drug Abuse2000–2002
- Immunization To Block The Central Effects Of NicotineNational Institute On Drug Abuse1997–1999
- Core--AnalyticNational Institute On Drug Abuse1997–1998
- Effects Of Dynorphin On Heroin AddictionNational Center For Research Resources1996–1997
- Effects Of Dynorphin 1-13 On Heroin AddictionNational Institute On Drug Abuse1993–1994
- Antibody Treatment Of Antidepressant ToxicityNational Institute Of Mental Health1992–1994
- Antibody Treatment Of Desipramine ToxicityNational Institute Of Mental Health1988–1990
- Antibody Treatment Of Desipramine ToxicityNational Institute Of Mental Health1986
